Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of parkinson's disease

Frontiers in Neuroscience

Volumn 10, Issue AUG, 2016, Pages

  Javed, Hayate ^a   Azimullah, Sheikh ^a   Haque, M Emdadul ^a   Ojha, Shreesh K ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

AM630; Cannabinoid agonist; Neurodegeneration; Neuroprotection; Parkinson's disease; Rotenone; caryophyllene; Trans caryophyllene

Indexed keywords

CANNABINOID 2 RECEPTOR; CARYOPHYLLENE; CATALASE; CYCLOOXYGENASE 2; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; NITRITE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84988447236     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2016.00321     Document Type: Article

References (59)

1. Al Mansouri, S., Ojha, S., Al Maamari, E., Al Ameri, M., Nurulain, S. M., and Bahi, A. (2014). The cannabinoid receptor 2 agonist, β-caryophyllene, reduced voluntary alcohol intake and attenuated ethanol-induced place preference and sensitivity in mice. Pharmacol. Biochem. Behav. 124, 260-268. doi: 10.1016/j.pbb.2014.06.025.
2. Arumugam, T. V., Cheng, Y. L., Choi, Y., Choi, Y. H., Yang, S., Yun, Y. K., et al. (2011). Evidence that β-secretase-mediated notch signaling induces neuronal cell death via the nuclear factor-βB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke. Mol. Pharmacol. 80, 23-31. doi: 10.1124/mol.111.071076.
3. Bahi, A., Al Mansouri, S., Al Memari, E., Al Ameri, M., Nurulain, S. M., and Ojha, S. (2014). β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol. Behav. 135, 119-124. doi: 10.1016/j.physbeh.2014.06.003.
4. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A., and Freeman, B. A. (1990). Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U.S.A. 87, 1620-1624.
5. Bento, A. F., Leite, D. F., Claudino, R. F., Hara, D. B., Leal, P. C., and Calixto, J. B. (2008). The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J. Leukoc. Biol. 84, 1213-1221. doi: 10.1189/jlb.0408231.
6. Bento, A. F., Marcon, R., Dutra, R. C., Claudino, R. F., Cola, M., Leite, D. F., et al. (2011). Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am. J. Pathol. 178, 1153-1166. doi: 10.1016/j.ajpath.2010.11.052.
7. Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J. H., et al. (2006). Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22, 404-420. doi: 10.1016/j.nbd.2005.12.003.
8. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306. doi: 10.1038/81834.
9. Bolognini, D., Cascio, M. G., Parolaro, D., and Pertwee, R. G. (2012). AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br. J. Pharmacol. 165, 2561-2574. doi: 10.1111/j.1476-5381.2011.01503.x.
10. Cadet, J. L., and Brannock, C. (1998). Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 32, 117-131. doi: 10.1016/S0197-0186(97)00031-4.
11. Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., and Greenamyre, J. T. (2009). A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34, 279-290. doi: 10.1016/j.nbd.2009.01.016.
12. Chang, H. J., Kim, H. J., and Chun, H. S. (2007). Quantitative Structure-Activity Relationship (QSAR) for neuroprotective activity of terpenoids. Life Sci. 80, 835-841. doi: 10.1016/j.lfs.2006.11.009.
13. Chen, X., and Tansey, M. G. (2011). "The role of neuroinflammation in Parkinson's disease," in Neuroinflammation, ed A. Minagar (London: Elsevier), 403-421.
14. Cho, J., Chang, H. J., Lee, S. K., Kim, H. J., Hwang, J. K., and Chun, H. S. (2007). Amelioration of dextran sulfate sodium-induced colitis in mice by oral administration of beta-caryophyllene, a sesquiterpene. Life Sci. 80, 932-939. doi: 10.1016/j.lfs.2006.11.038.
15. Choi, I. Y., Ju, C., Anthony Jalin, A. M., Lee da, I., Prather, P. L., and Kim, W. K. (2013). Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am. J. Pathol. 182, 928-939. doi: 10.1016/j.ajpath.2012.11.024.
16. Concannon, R. M., Okine, B. N., Finn, D. P., and Dowd, E. (2015). Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease. Exp. Neurol. 269, 133-141. doi: 10.1016/j.expneurol.2015.04.007.
17. Correa, F., Mestre, L., Molina-Holgado, E., Arevalo-Martin, A., Docagne, F., Romero, E., et al. (2005). The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev. Med. Chem. 5, 671-675. doi: 10.2174/1389557054368790.
18. Fernandez-Ruiz, J., Romero, J., Velasco, G., Tolon, R. M., Ramos, J. A., and Guzman, M. (2007). Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 39-45. doi: 10.1016/j.tips.2006.11.001.
19. Galdino, P. M., Nascimento, M. V., Florentino, I. F., Lino, R. C., Fajemiroye, J. O., Chaibub, B. A., et al. (2012). The anxiolytic-like effect of an essential oil derived from Spiranthera odoratissima A. St. Hil. leaves and its major component, β-caryophyllene, in male mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 38, 276-284. doi: 10.1016/j.pnpbp.2012.04.012.
20. García, C., Palomo-Garo, C., García-Arencibia, M., Ramos, J., Pertwee, R., and Fernández-Ruiz, J. (2011). Symptom-relieving and neuroprotective effects of the phytocannabinoid δ9-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 163, 1495-1506. doi: 10.1111/j.1476-5381.2011.01278.x.
21. García, M. C., Cinquina, V., Palomo-Garo, C., Rábano, A., and Fernández-Ruiz, J. (2015). Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci. Lett. 587, 1-4. doi: 10.1016/j.neulet.2014.12.003.
22. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J. Z., Xie, X. Q., et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. U.S.A. 105, 9099-9104. doi: 10.1073/pnas.0803601105.
23. Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., and García, C. (2016). Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation inParkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 200-208. doi: 10.1016/j.pnpbp.2015.03.017.
24. Gordon, R., Anantharam, V., Kanthasamy, A. G., and Kanthasamy, A. (2012). Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J. Neuroinflammation 9:82. doi: 10.1186/1742-2094-9-82.
25. Hald, A., and Lotharius, J. (2005). Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp. Neurol. 193, 279-290. doi: 10.1016/j.expneurol.2005.01.013.
26. Hill, M. N., Hillard, C. J., Bambico, F. R., Patel, S., Gorzalka, B. B., and Gobbi, G. (2009). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol. Sci. 30, 484-493. doi: 10.1016/j.tips.2009.06.006.
27. Hirsch, E. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., and Michel, P. P. (2003). The role of glial reaction and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci. 991, 214-228. doi: 10.1111/j.1749-6632.2003.tb07478.x.
28. Hosohata, K., Quock, R. M., Hosohata, Y., Burkey, T. H., Makriyannis, A., Consroe, P., et al. (1997). AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci. 61, PL115-PL118. doi: 10.1016/S0024-3205(97)00596-1.
29. Hu, L. F., Lu, M., Tiong, C. X., Dawe, G. S., Hu, G., and Bian, J. S. (2010). Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 9, 135-146. doi: 10.1111/j.1474-9726.2009.00543.x.
30. Jenner, P. (2003). Oxidative stress in Parkinson's disease. Ann. Neurol. 53, S26-S36. doi: 10.1016/j.freeradbiomed.2012.05.024.
31. Johnson, D. A., and Johnson, J. A. (2015). Nrf2-a therapeutic target for the treatment of neurodegenerative diseases. Free Radic. Biol. Med. 88(Pt B), 253-267. doi: 10.1016/j.freeradbiomed.2015.07.147.
32. Klein, T. W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5, 400-411. doi: 10.1038/nri1602.
33. Lee, J. K., Tran, T., and Tansey, M. G. (2009). Neuroinflammation in Parkinson's disease. J. Neuroimmune. Pharmacol. 4, 419-429. doi: 10.1186/s40035-015-0042-0.
34. Leonhardt, V., Leal-Cardoso, J. H., Lahlou, S., Albuquerque, A. A., Porto, R. S., Celedonio, N. R., et al. (2010). Antispasmodic effects of essential oil of Pterodon polygalaeflorus and its main constituent β-caryophyllene on rat isolated ileum. Fundam. Clin. Pharmacol. 24, 749-758. doi: 10.1111/j.1472-8206.2009.00800.x.
35. Marchalant, Y., Cerbai, F., Brothers, H. M., and Wenk, G. L. (2008). Cannabinoid receptor stimulation is antiinflammatory and improves memory in old rats. Neurobiol. Aging 29, 1894-1901. doi: 10.1016/j.neurobiolaging.2007.04.028.
36. Medeiros, R., Passos, G. F., Vitor, C. E., Koepp, J., Mazzuco, T. L., Pianowski, L. F., et al. (2007). Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw. Br. J. Pharmacol. 151, 618-627. doi: 10.1038/sj.bjp.0707270.
37. Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., et al. (2006). Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's Disease. Clin. Neurosci. Res. 6, 261-281. doi: 10.1016/j.cnr.2006.09.006.
38. Ojha, S., Javed, H., Azimullah, S., Abul Khair, S. B., and Haque, M. E. (2015). Glycyrrhizic acid attenuates neuroinflammation and oxidative stress in rotenone model of Parkinson's disease. Neurotox. Res. 29, 275-287. doi: 10.1007/s12640-015-9579-z.
39. Palazuelos, J., Aguado, T., Pazos, M. R., Julien, B., Carrasco, C., Resel, E., et al. (2009). Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132(Pt 11), 3152-3164. doi: 10.1093/brain/awp239.
40. Palazuelos, J., Davoust, N., Julien, B., Hatterer, E., Aguado, T., Mechoulam, R., et al. (2008). The CB2 cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 283, 13320-13329. doi: 10.1074/jbc. M707960200.
41. Passos, G. F., Fernandes, E. S., Campos, M. M., Araujo, J. G., Pesquero, J. L., Souza, G. E., et al. (2004). Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J. Immunol. 172, 1839-1847. doi: 10.4049/jimmunol.172.3.1839.
42. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631. doi: 10.1124/pr.110.003004.
43. Price, D. A., Martinez, A. A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., et al. (2009). WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the MPTP mouse model of Parkinson's disease. Eur. J. Neurosci. 29, 2177-2186. doi: 10.1111/j.1460-9568.2009.06764.x.
44. Ramírez, B. G., Blázquez, C., Gómez del Pulgar, T., Guzmán, M., and de Ceballos, M. L. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904-1913. doi: 10.1523/JNEUROSCI.4540-04.2005.
45. Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres-Becker, I., et al. (2009). Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57, 1154-1167. doi: 10.1002/glia.20838.
46. Schapira, A. H. (1989). Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269. doi: 10.1016/s0140-6736(89)92366-0.
47. Sharma, C., Al Kaabi, J. M., Nurulain, S. M., Goyal, S. N., Kamal, M. A., and Ojha, S. (2016). Polypharmacological properties and therapeutic potential of β-Caryophyllene: a dietary phytocannabinoid of pharmaceutical promise. Curr. Pharm. Des. 22, 3237-3264.
48. Shen, H., Hu, X., Liu, C., Wang, S., Zhang, W., Gao, H., et al. (2010). Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol. Dis. 37, 711-722. doi: 10.1016/j.nbd.2009.12.010.
49. Sherer, T. B., Richardson, J. R., Testa, C. M., Seo, B. B., Panov, A. V., Yagi, T., et al. (2007). Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 100, 1469-1479. doi: 10.1111/j.1471-4159.2006.04333.x.
50. Shimohama, S., Sawada, H., Kitamura, Y., and Taniguchi, T. (2003). Disease model: Parkinson's disease. Trends Mol. Med. 9, 360-365. doi: 10.3389/fnmol.2016.00007.
51. Sibbald, B. (2005). Conditional okay for cannabis prescription drug. CMAJ 172, 1672. doi: 10.1503/cmaj.050628.
52. Singh, G., Marimuthu, P., de Heluani, C. S., and Catalan, C. A. (2006). Antioxidant and biocidal activities of Carum nigrum (seed) essential oil, oleoresin, and their selected components. J. Agric. Food Chem. 54, 174-181. doi: 10.1021/jf0518610.
53. Tapias, V., Cannon, J. R., and Greenamyre, J. T. (2014). Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson's disease. Neurobiol. Aging. 35, 1162-1176. doi: 10.1016/j.neurobiolaging.2013.10.077.
54. Tapias, V., Escames, G., López, L. C., López, A., Camacho, E., Carrión, M. D., et al. (2009). Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J. Neurosci. Res. 87, 3002-3010. doi: 10.1002/jnr.22123.
55. Thakur, P., and Nehru, B. (2013). Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease. Neuroscience 231, 420-431. doi: 10.1016/j.neuroscience.2012.11.006.
56. Yan, J., Fu, Q., Cheng, L., Zhai, M., Wu, W., Huang, L., et al. (2014). Inflammatory response in Parkinson's disease (Review). Mol. Med. Rep. 10, 2223-2233. doi: 10.3892/mmr.2014.2563.
57. Zanettini, C., Panlilio, L. V., Alicki, M., Goldberg, S. R., Haller, J., and Yasar, S. (2011). Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front. Behav. Neurosci. 5:57. doi: 10.3389/fnbeh.2011.00057.
58. Zhang, H. Y., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., et al. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc. Natl. Acad. Sci. U.S.A. 111, E5007-E5015. doi: 10.1073/pnas.1413210111.
59. Zhao, Y., Liu, Y., Zhang, W., Xue, J., Wu, Y. Z., Xu, W., et al. (2010). WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur. J. Pharmacol. 649, 285-292. doi: 10.1016/j.ejphar.2010.09.027.